MAR 11, 2019 2:54 PM PDT

Fast-Acting Drug For Depression

WRITTEN BY: Nouran Amin

Many individuals going through depression gain little benefit from treatments whether drugs or talk therapy. Depression represents one of the greatest unmet needs in psychiatry. Now, the Food and Drug Administration (FDA) approved a fast-acting prescription antidepressant: a nasal spray version of the widely used anesthetic drug ketamine.

A colored positron emission tomography scan of the brain of a depressed person, highlighting regions (in red) where blood flow and metabolic activity are unusually low. CreditWDCN/Univ. College London, via Science Source.

“Thank goodness we now have something with a different mechanism of action than previous antidepressants,” said Dr. Erick Turner, a former F.D.A. reviewer and an associate professor of psychiatry at Oregon Health & Science University. “But I’m skeptical of the hype, because in this world it’s like Lucy holding the football for Charlie Brown: Each time we get our hopes up, the football gets pulled away.”

The newly approved fast-acting drug, now called esketamine, will bring on a shift from the Prozac era of antidepressant drugs. The spray was developed by Janssen Pharmaceuticals Inc., a branch of Johnson & Johnson, and will be marketed under the name Spravato.

“These are exciting times, for sure,” said Dr. Todd Gould, an associate professor of psychiatry in the University of Maryland School of Medicine. “We have drugs that work rapidly to treat a very severe illness.”

Spravato (esketamine) “works in a different way than traditional antidepressants,” with results in a matter of hours.

Credit: Janssen Pharmaceuticals, Inc.

Esketamine provides renewed hope in treating serious mood problems. Current drug treatments, like Prozac and similar drugs, work to enhance the activity of brain chemical like messengers like serotonin—however, these drugs take weeks or even months for their effects to be felt.

“We’ve had nothing new in 30 years,” said Steven Hollon, a professor of psychiatry and behavior sciences at Vanderbilt University. “So if this drug is an effective way to get a more rapid response in people who are treatment resistant, and we can use it safely, then it could be a godsend.”

Learn more:

Source: NY Times

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 22, 2019
Health & Medicine
NOV 22, 2019
Federal Government Weighs in on Marijuana and Opioid Addiction
The U.S. government is weighing in on the hot topic of whether or not medical marijuana is a successful tool in treating opioid addiction by barring the us...
DEC 17, 2019
Cell & Molecular Biology
DEC 17, 2019
A New Tool for Assessing the Impact of Drugs on Single Cells
When scientists assess the impact of a treatment like a drug on cells, they usually generally rely on large populations of cells to find general trends....
DEC 19, 2019
Technology
DEC 19, 2019
Can a 'Lemon' help develop new drugs?
Although artificial intelligence has many advantages in the drug discovery process, challenges still remain--one being the ability for machine learning to ...
DEC 23, 2019
Drug Discovery & Development
DEC 23, 2019
FDA Approves New Schizophrenic Drug
The US Food and Drug Administration (FDA) has approved an atypical antipsychotic Caplyta (lumateperone; Intra-Cellular Therapies) for the treating schizoph...
DEC 27, 2019
Drug Discovery & Development
DEC 27, 2019
New Drug to Treat Migraines Approved by FDA
Over 1 in 10 people around the world- or 780 million people. Three times more common in women than in men, until now, most treatments have been preventativ...
FEB 03, 2020
Drug Discovery & Development
FEB 03, 2020
HIV Viral Structures Improve Therapeutics
Researchers have recently discovered how a powerful class of HIV drugs bind to a key piece of HIV machinery. Their findings, for the first time, shows how ...
Loading Comments...